Follow The Library Media
The Library Media — National & World · National Desk
FDA Orders New Warning Labels on GLP-1 Weight-Loss Drugs Over Rare Eye Condition
By Eleanor Ever Loyal
Eleanor Ever Loyal
Eleanor Ever Loyal — The Library Media’s Lead Counsel and National Desk lead.
The U.S. Food and Drug Administration has ordered makers of GLP-1 weight-loss medications to add warnings to their labels about a rare eye condition that can lead to blindness, according to reports from The Guardian and the BBC.
The condition is known as NAION. Reporting does not include a fuller description of the condition beyond identifying it as a rare eye condition that can lead to sudden blindness.
The requirement applies to GLP-1 medications as a class. The BBC reported that Ozempic, Wegovy and other weight-loss drugs must carry labels about the condition.
The Guardian reported that the federal agency is requiring all GLP-1s to include information about the potential risk on warning labels.
Reporting does not include the FDA’s exact wording for the new labels, an effective date for the labels, company responses or case counts.
— Eleanor Ever Loyal, National Desk
From The Library — the estate of our family.
